COX-2 in cancer: Gordian knot or achilles heel?

Frontiers in Pharmacology

Volumn 4 MAR, Issue , 2013, Pages

  Stasinopoulos, Ioannis ^a   Shah, Tariq ^a   Penet, Marie France ^a   Krishnamachary, Balaji ^a   Bhujwalla, Zaver M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

COX 2 and HIF 1; COX 2 and LEF 1; COX 2 inhibitors; Cyclooxygenase 2; Inflammation and cancer; Inflammation and hypoxia; Invasion; Metastasis

Indexed keywords

AROMATASE INHIBITOR; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SMALL INTERFERING RNA; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ACIDITY; ADAPTATION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CELL INVASION; COLON ADENOMA; COLORECTAL CARCINOMA; COX 2 GENE; DRUG TARGETING; EXTRACELLULAR SPACE; GENE EXPRESSION; GENE SILENCING; HUMAN; HYPOXIA; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; ONCOGENE; PH; PHENOTYPE; PROTEIN FUNCTION; TUMOR MICROENVIRONMENT; BLOOD VESSEL; BREAST METASTASIS; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL STRUCTURE; CELL SURVIVAL; CELL TRANSFORMATION; ENVIRONMENTAL CHANGE; EXTRACELLULAR MATRIX; LYMPH VESSEL; TUMOR INVASION;

EID: 84881538331     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00034     Document Type: Article

References (66)

1. Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., and Taubert, K. A. (2007). Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115, 1634-1642.
2. Arber, N., Eagle, C. J., Spicak, J., Racz, I., Dite, P., Hajer, J., et al. (2006). Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355, 885-895.
3. Baron, J. A., Sandler, R. S., Bresalier, R. S., Lanas, A., Morton, D. G., Riddell, R., et al. (2008). Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 372, 1756-1764.
4. Baumgarten, S. C., and Frasor, J. (2012). Minireview: inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol. Endocrinol. 26, 360-371.
5. Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Solomon, S. D., Kim, K., et al. (2006). Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355, 873-884.
6. Castellone, M. D., Teramoto, H., Williams, B. O., Druey, K. M., and Gutkind, J. S. (2005). Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310, 1504-1510.
7. Chang, S. H., Liu, C. H., Conway, R., Han, D. K., Nithipatikom, K., Trifan, O. C., et al. (2004). Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc. Natl. Acad. Sci. U.S.A. 101, 591-596.
8. Chow, L. W., Yip, A. Y., Loo, W. T., Lam, C. K., and Toi, M. (2008). Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J. Steroid Biochem. Mol. Biol. 111, 13-17.
9. Choy, H., and Milas, L. (2003). Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J. Natl. Cancer Inst. 95, 1440-1452.
10. Chun, K. S., and Surh, Y. J. (2004). Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem. Pharmacol. 68, 1089-1100.
11. Conklin, M. W., Eickhoff, J. C., Riching, K. M., Pehlke, C. A., Eliceiri, K. W., Provenzano, P. P., et al. (2011). Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am. J. Pathol. 178, 1221-1232.
12. Diaz-Cruz, E. S., and Brueggemeier, R. W. (2006). Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med. Chem. 6, 221-232.
13. DiDonato, J. A., Mercurio, F., and Karin, M. (2012). NF-kappaB and the link between inflammation and cancer. Immunol. Rev. 246, 379-400.
14. Falandry, C., Debled, M., Bachelot, T., Delozier, T., Cretin, J., Romestaing, P., et al. (2009). Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res. Treat. 116, 501-508.
15. Fulton, A. M. (1988). The role of eicosanoids in tumor metastasis. Prostaglandins Leukot. Essent. Fatty Acids 34, 229-237.
16. Gilbert, C. A., and Slingerland, J. M. (2013). Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu. Rev. Med. 64, 45-57.
17. Gillies, R. J., Bhujwalla, Z. M., Evelhoch, J., Garwood, M., Neeman, M., Robinson, S. P., et al. (2000). Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia 2, 139-151.
18. Glover, J. A., Hughes, C. M., Cantwell, M. M., and Murray, L. J. (2011). A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer. Br. J. Cancer 105, 13-17.
19. Glunde, K., Bhujwalla, Z. M., and Ronen, S. M. (2011). Choline metabolism in malignant transformation. Nat. Rev. Cancer 11, 835-848.
20. Glunde, K., Shah, T., Winnard, P. T. Jr., Raman, V., Takagi, T., Vesuna, F., et al. (2008). Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res. 68, 172-180.
21. Greene, E. R., Huang, S., Serhan, C. N., and Panigrahy, D. (2011). Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat. 96, 27-36.
22. Grosch, S., Maier, T. J., Schiffmann, S., and Geisslinger, G. (2006). Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 98, 736-747.
23. Gupta, G. P., Nguyen, D. X., Chiang, A. C., Bos, P. D., Kim, J. Y., Nadal, C., et al. (2007). Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446, 765-770.
24. Haeggstrom, J. Z., Rinaldo-Matthis, A., Wheelock, C. E., and Wetterholm, A. (2010). Advances in eicosanoid research, novel therapeutic implications. Biochem. Biophys. Res. Commun. 396, 135-139.
25. Howe, L. R. (2007). Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 9, 210.
26. Imtiyaz, H. Z., and Simon, M. C. (2010). Hypoxia-inducible factors as essential regulators of inflammation. Curr. Top. Microbiol. Immunol 345, 105-120.
27. Jung, Y. J., Isaacs, J. S., Lee, S., Trepel, J., and Neckers, L. (2003). IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17, 2115-2117.
28. Kaiser, E., Chiba, P., and Zaky, K. (1990). Phospholipases in biology and medicine. Clin. Biochem. 23, 349-370.
29. Kakkad, S. M., Solaiyappan, M., Argani, P., Sukumar, S., Jacobs, L. K., Leibfritz, D., et al. (2012). Collagen I fiber density increases in lymph node positive breast cancers: pilot study. J. Biomed. Opt. 17, 116017.
30. Katoh, H., Hosono, K., Ito, Y., Suzuki, T., Ogawa, Y., Kubo, H., et al. (2010). COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems. Am. J. Pathol. 176, 1469-1483.
31. Kerlikowske, K., Molinaro, A. M., Gauthier, M. L., Berman, H. K., Waldman, F., Bennington, J., et al. (2010). Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J. Natl. Cancer Inst. 102, 627-637.
32. Kim, H. S., Moon, H. G., Han, W., Yom, C. K., Kim, W. H., Kim, J. H., et al. (2012). COX2 overexpression is a prognostic marker for stage III breast cancer. Breast Cancer Res. Treat. 132, 51-59.
33. Koehne, C. H., and Dubois, R. N. (2004). COX-2 inhibition and colorectal cancer. Semin. Oncol. 31, 12-21.
34. Krysan, K., Reckamp, K. L., Sharma, S., and Dubinett, S. M. (2006). The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med. Chem. 6, 209-220.
35. Liu, J. F., Fong, Y. C., Chang, C. S., Huang, C. Y., Chen, H. T., Yang, W. H., et al. (2010). Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells. Mol. Cancer 9, 43.
36. Liu, Y. V., and Semenza, G. L. (2007). RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization. Cell Cycle 6, 656-659.
37. Lyons, T. R., O'Brien, J., Borges, V. F., Conklin, M. W., Keely, P. J., Eliceiri, K. W., et al. (2011). Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat. Med. 17, 1109-1115.
38. Martin, L. A., Davies, G. L., Weigel, M. T., Betambeau, N., Hills, M. J., Salter, J., et al. (2010). Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. Breast Cancer Res. Treat. 123, 829-836.
39. Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J. (1997). Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. U.S.A. 94, 8104-8109.
40. Menter, D. G., and Dubois, R. N. (2012). Prostaglandins in cancer cell adhesion, migration, and invasion. Int. J. Cell Biol. 2012, 723-419.
41. Menter, D. G., Schilsky, R. L., and Dubois, R. N. (2010). Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin. Cancer Res. 16, 1384-1390.
42. Molla, M., and Panes, J. (2007). Radiation-induced intestinal inflammation. World J. Gastroenterol. 13, 3043-3046.
43. Needleman, P., Turk, J., Jakschik, B. A., Morrison, A. R., and Lefkowith, J. B. (1986). Arachidonic acid metabolism. Annu. Rev. Biochem. 55, 69-102.
44. Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R. P., and Kalinski, P. (2011). PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 71, 7463-7470.
45. Ouchi, N., Parker, J. L., Lugus, J. J., and Walsh, K. (2011). Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11, 85-97.
46. Potente, M., Gerhardt, H., and Carmeliet, P. (2011). Basic and therapeutic aspects of angiogenesis. Cell 146, 873-887.
47. Pradono, P., Tazawa, R., Maemondo, M., Tanaka, M., Usui, K., Saijo, Y., et al. (2002). Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 62, 63-66.
48. Rundhaug, J. E., and Fischer, S. M. (2008). Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis. Photochem. Photobiol. 84, 322-329.
49. Samuelsson, B., Goldyne, M., Granstrom, E., Hamberg, M., Hammarstrom, S., and Malmsten, C. (1978). Prostaglandins and thromboxanes. Annu. Rev. Biochem. 47, 997-1029.
50. Schedin, P., and Keely, P. J. (2011). Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. Cold Spring Harb. Perspect. Biol. 3, a003228.
51. Schonthal, A. H., Chen, T. C., Hofman, F. M., Louie, S. G., and Petasis, N. A. (2008). Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin. Investig. Drugs 17, 197-208.
52. Semenza, G. L. (2012). Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33, 207-214.
53. Shah, T., Stasinopoulos, I., Wildes, F., Kakkad, S., Artemov, D., and Bhujwalla, Z. M. (2012). Noninvasive imaging identifies new roles for cyclooxygenase-2 in choline and lipid metabolism of human breast cancer cells. NMR Biomed. 25, 746-754.
54. Shay, J. E., and Simon, C. M. (2012). Hypoxia-inducible factors: crosstalk between inflammation and metabolism. Semin. Cell Dev. Biol. 23, 389-394.
55. Singh-Ranger, G., Salhab, M., and Mokbel, K. (2008). The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res. Treat. 109, 189-198.
56. Smith, W. L., Dewitt, D. L., and Garavito, R. M. (2000). Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145-182.
57. Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., et al. (2008). Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117, 2104-2113.
58. Stasinopoulos, I., Greenwood, T., Glunde, K., and Bhujwalla, Z. M. (2012). Prostaglandin E2 promotes the nuclear accumulation of lymphoid enhancer factor-1 in poorly differentiated breast cancer cells. Prostaglandins Other Lipid Mediat. 99, 9-14.
59. Stasinopoulos, I., Mori, N., and Bhujwalla, Z. M. (2008). The malignant phenotype of breast cancer cells is reduced by COX-2 silencing. Neoplasia 10, 1163-1169.
60. Stasinopoulos, I., O'Brien, D. R., and Bhujwalla, Z. M. (2009). Inflammation, but not hypoxia, mediated HIF-1alpha activation depends on COX-2. Cancer Biol. Ther. 8, 31-35.
61. Stasinopoulos, I., O'Brien, D. R., Wildes, F., Glunde, K., and Bhujwalla, Z. M. (2007). Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol. Cancer Res. 5, 435-442.
62. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., et al. (2000). The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952.
63. van der Donk, W. A., Tsai, A. L., and Kulmacz, R. J. (2002). The cyclooxygenase reaction mechanism. Biochemistry 41, 15451-15458.
64. Wallace, J. L. (2005). Recent advances in gastric ulcer therapeutics. Curr. Opin. Pharmacol. 5, 573-577
65. Wang, D., Mann, J. R., and Dubois, R. N. (2005). The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128, 1445-1461.
66. Xu, L., Zhang, L., Yi, Y., Kang, H. K., and Datta, S. K. (2004). Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat. Med. 10, 411-415.